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ABSTRACT
Carboxylesterases (CES) catalyze both hydrolytic and synthetic reactions and play
important roles in drug metabolism and lipid mobilization. Many factors such as age
and dietary supplements have been shown to regulate the CES expression. The
expression of CES1 shows the developmental regulation and is highly induced by
antioxidants. The goals of this project were to determine whether CES2, like CES1, is
developmentally regulated and to investigate how antioxidants induced the expression
of CES1 at the molecular level.

The ontogenic studies showed the mRNA levels of CES2 exhibited a postnatal surge
(1-31 days versus 35-70 days) in both liver and duodenum. The levels of CES2
protein increased with age as well. However, individual donor multi-sampling CES2
expression studies showed the significant correlation between the duodenum and
jejunum but insignificant correlation between the liver and duodenum. Moreover, the
metabolic enzyme cytochrome P450 3A4 (CYP3A4) which share substrates with
CES2 in many case have a comparable age related expression pattern but the mRNA
level of CYP3A4 in the duodenum showed otherwise.

The mechanistic studies on CES1 induction used the dissected regulatory sequence of
the CES1A1 gene to locate the element supporting the transactivation. A novel
element was identified and designated as sensitizing/antioxidant response element

(S/ARE). Comparing with the known antioxidant element ARE4, the novel element
supported whereas the ARE4 element repressed the transactivation. The
Electrophoretic mobility shift assay and Chromatin immunoprecipitation experiments
demonstrated that the S/ARE element serves as a major site to interact with the
CES1A1 gene and both elements were bound by nuclear factor-E2 related factor-2
(Nrf2).

In conclusion, CES2 and CYP3A4 are expressed under developmental regulation and
whether the regulation occurs in a gene-dependent or an organ-dependent manner.
Both positive and negative Nrf2 response elements exist even within the same gene.
The identification of ARE4 supported Nrf2 repression, given the fact that Nrf2 is
generally considered to confer transactivation activity.
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(2012). Antioxidant sulforaphane and sensitizer trinitrobenzene sulfonate induce
carboxylesterase-1 through a novel element transactivated by nuclear factor-E2
related factor-2. Biochem Pharmacol, 84(6), 864-871. Published manuscript text,
supplemental text and figures of unpublished experimentation, results, and
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CHAPTER 1

INTRODUCTION

CARBOXYLESTERASES
1. Overview of carboxylesterases
Carboxylesterases (CES, E.C.3.1.1.1) constitute a large class of enzymes that play
important roles in drug metabolism and lipid mobilization [1-4]. These enzymes not
only catalyze hydrolytic and synthetic reactions but also interact with other proteins.
Their primary function is hydrolysis. The foreign carboxylic acid ester, amides and
thioesters compounds are hydrolyzed into two components by carboxylesterases (
Figure 1.1). Hydrolysis of compounds usually causes severe changes in the electronic
charge and the structure and completely affects the pharmacokinetic and
pharmacodynamics characteristics of compounds [5-9]. In addition, numerous
endogenous substrates such as triglycerides and cholesterol esters also are hydrolyzed
by carboxylesterases [4-7] and relocate to different organelles through the
re-esterification – hydrolysis cycle [10].
Multiple forms of carboxylesterases are expressed in all mammalian species. Based
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on the current approach, there are six families of all mammalian carboxylesterases,
CES1, CES2, CES3, CES4, CES5, and CES6 and the members of each family share
at least 60% of the sequence identity [6]. The two major families of the
carboxylesterases are CES1 and CES2. The largest number of carboxylesterases
belong to CES1 and eight subfamilies have been assigned [6]. The CES1 of humans,
rabbits and monkeys belong to the CES1A subfamily and the CES1 of the mice, rats
and hamsters are covered by CES1B. The CES1 of pigs, dogs and cats are members
of CES1C [11-18]. Almost all CES1 subfamilies are expressed mainly in the liver
expect CES1G [16, 19]. In contrast, CES2 are expressed mainly in the intestines,
especially in the small intestines. The CES2 family contains human (CES2A1), rat
(CES2A10), mice (CES2A6) and rabbit isoenzymes (Table 1.1) [20-27].
There are seven distinct carboxylesterase genes found in the human genome, CES1A1,
CES1A2, CES1A3, CES2, CES3, CES5 and CES6 respectively [5, 28, 29]. With
39-44% sequences identity [28, 29], the major differences between the CES1A1 and
CES1A2 genes are in the promoters and leader sequence regions. Their functional
mature proteins have four different amino acids in the signal peptide. The CES1A3
gene is considered a pseudo gene because of a premature stop codon. Humans can
only express either CES1A2 or CES1A3. Unlike the CES1 family, there is only one
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member from each CES2, CES3, CES5 and CES6 expressed in humans [5]. The
CES1 is found as a trimer or hexamer and the CES2 and CES3 exist as a monomer.
The CES2 gene is expressed at different levels of mRNA and in proteins in different
tissues through their transcription by three alternative promoters and two in-frame
ATG’s [30]. CES3 has 40% identical sequences compared with CES1 and CES2.
However, it shows very low activity with commonly used substrates [31]. CES5 and
CES6 have more glycosylation sites than others CESs and both of them are the
secretory protein. The activities of CES5 and CES6 remain unclear.
The human liver expresses higher level of carboxylesterases than other organs and
shows the highest overall carboxylesterase activity. In the liver, larynx, esophagus and
lungs, CES1 has been found. CES2 is mainly found in the gastrointestinal track, the
kidney and the liver (Table 1.1). CES3 shows a low level in the trachea, intestine and
placenta [32]. In contrast, the rodents contain abundant serum carboxylesterases and
none of common human carboxylesterases (CES1, CES2 and CES3) have been found
in normal serum [33].
The substrate specificity of carboxylesterases is considered to be ample and
overlapping. The substrate specificity of two major human carboxylesterases
isozymes (CES1 and CES2) have been characterized in the past decade [3, 5, 6, 34].
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The substrates of CES1 generally have a small alcohol moiety and a large acyl moiety.
In contrast, substrates of CES2 have a large alcohol moiety and a small acyl moiety
(Figure 1.4). For example, CES1 rather than CES2 rapidly hydrolyzes
methylphenidate since the acyl moiety (methylphenidate carboxylate) is much larger
than the alcohol moiety (methanol) [7]. In the antiplatelet agent, prasugrel, the acyl
moiety is much smaller than the alcohol moiety, so it is mostly hydrolyzed by CES2
[35]. If the compound has more than one ester bonds, it also fit this alcohol/acid size based preference. For example, cocaine contains two ester bonds and can be
hydrolyzed to ecgonine, methanol, and benzoic acid. CES1 breaks the ester bond
which connects the largest acid (ecgonine) and the small alcohol (methanol) and
CES2 hydrolyzes benzoate – ecgoninyl ester (Figure 1.). However, there are some
exceptions to this alcohol/acid size based rule.
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Oseltamivir

Spironolactone

Irinotecan

Diisopropylfluorophosphate

Paraoxon

Fatty acid ethyl ester synthesis

Transesterification of Cocaine

Figure 1.1 Representative drugs chemical structures which are metabolized by
carboxylesterases. The arrows show chemical bonds which are hydrolyzed by
carboxylesterases.
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Table 1.1 Tissuue distributio
ons of CES 1 and CES2
2 in mammaals [32].
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Methylphenidate

Prasugrel

Cocaine

Figure 1.2 Examples of substrate specificity of human carboxylesterases CES1 and
CES2. The arrows indicate bonds hydrolyzed by carboxylesterases and the boxes
show the acid moieties of compounds.
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2. Ontogenic Expression
The expression of carboxylesterases shows developmental regulation in humans and
rodents. During developmental stages, the human hydrolytic capacity shows an early
surge in the neonatal stage and remains high through adolescence [36, 37]. CES1
mRNA has a postnatal surge in first two months [36]. In addition, adult humans
express significantly higher carboxylesterase than children and children express much
higher CES than fetuses. Large inter-individual variability (mRNA (430-fold), protein
(100-fold) and hydrolytic activity (127-fold)) are found in the child and fetal groups
but not in the adult group. That indicates the pharmacokinetics parameters of ester
drugs in children may vary widely and the dosage of ester drugs needs to be carefully
adjusted in children. [37]
CES1 expression shows a surge during post-neonatal stage. The mRNA and protein of
the CES1 increases 4–7-fold in the hydrolysis and the expression analyses between
the 1–31days and 35–70days groups. However, the other 3 pediatric groups (35–70,
89–119, 123–198) show similar levels. The 1–31d group and other 3 pediatric groups
show only 10% and 50% of the expression level of adult group [37]. Based on these
results, dosing regimens of ester drugs should be extra carefully monitored to prevent
the possible side effects [37].
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For the rat, there are no hydrolases A or B. Two major rat carboxylesterases are
expressed in one to two weeks old rats [38]. Their intrinsic hydrolytic clearance is
only 3% of adults. The clearance of four weeks old rats is less than half that of adults
rats [39]. Moreover, animals are extremely sensitive to pesticides such as
organophosphates and pyrethroids. Carboxylesterases detoxify them through
hydrolysis or a scavenging mechanism.

Interestingly, the inducibility of

carboxylesterases shows an inverse relationship with age. The mRNA, protein and
catalytic levels of six major carboxylesterases in neonatal mice (10 days of age) show
a greater extent of induction than the adult mice after phenobarbital treatment [40].

9

3. Xenobiotic regulation
The catalytic activity of carboxylesterases can be manipulated by activators or
inhibitors[57]. Pinacolone has been observed to increase in vitro and in vivo activities
of carboxylesterases [58]. Acetone, a commonly used solvent, also shows the ability
to enhance enzyme activity by increasing the accessibility of the substrate [58].
Chemicals induce or suppress the expression of carboxylesterase through different
signaling pathways. There are various regulation pathways of induction which may
lead to the differences. The inducers of carboxylesterases expression show differences
in species in induction. Some factors which regulate the expression show the species
differences and some do not. The glucocorticoid drug, dexamethasone, increases the
expression of human carboxylesterases [41] but decreases the various rat
carboxylesterases even as low as the nanomolar (nM) level [42]. On the other hand,
phenobarbital, the most widely used anticonvulsant, induces the expression of
carboxylesterases across species [41, 43] through the constitutive androstane receptor
(CAR) and pregnane X receptor pathways (PXR) [44, 45]. Guggulsterone upregulates
the expression of human carboxylesterases through transcription factor, nuclear factor
(erythroid-derived 2)-like 2 (Nrf2) [46-48]. Moreover, 3-methylcholaanthrene is a
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ligand of the aryl hydrocarbon receptor (AhR) and only increases the enzyme in rats
[49].
Compounds with similar structures, may not have the same regulatory effect. Both
dexamethasone

and

pregnenolone

16

α

-

carbonitrile

(PCN)

contain

cyclopenta[a]phenanthrene as a basic structure. However, dexamethasone suppresses
carboxylesterases expression and PCN moderately induce the expression [19, 42].
Some chemicals have similar ability to induce the cytochrome P450 (CYP) enzymes
but may have the reverse effect in regulating carboxylesterases. For example,
isoniazid and streptozotocin, inducers of CYP2E1, show the opposite effect of
carboxylesterases. Streptozotocin is a weak inducer and isoniazid strongly suppresses
the expression [19, 50]. 3 – methylcholanthrene and β - naphthoflavone induce
carboxylesterases but have the opposite effect of CYP 1A. The first compound
induces the hydrolase S but the second one suppresses it [19, 50].
Antioxidants and sensitizers are two types of chemicals also show the induction of
CES. The induction of this carboxylesterase by antioxidants is mediated by Nrf2 [22].
This transcription factor recognizes the antioxidant response element (ARE) and
confers transactivation [23]. RNA interference against Nrf2 cancels CES1 induction
by antioxidants [22]. The majority of skin sensitizers, on the other hand, are
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sulfhydryl reactive agents and have been n to react with Kelch-like ECH associated
protein-1 (Keap1) [18, 21], an inhibitor of Nrf2. The Kelch-like ECH–associated
protein 1 (Keap1) is a cysteine rich protein and serves as a regulator of Nrf2. Keap1
and Nrf2 play a central role in the protection of cells against antioxidants and
sensitizers through inducing expression of many cytoprotective genes such as
carboxylesterase1. Under uninduced conditions, Nrf2 is ubiquitinated by the complex
and rapidly degraded in proteasomes. This degradation processes regulate Nrf2
protein and induce stabilization of Nrf2. Upon exposure to antioxidants and
sensitizers, these small molecules interact with the reactive cysteine residues of Keap1
and lead to dissociation of Nrf2 from Keap1-Nrf2 complex. Nrf2 translocates from
cytoplasm to nucleus and transactivates target genes Nrf2 show transactions through
binding with antioxidant response element of (ARE) in the promoter regions of
upstream regulatory sequences [51-54]. Interaction with Keap1 by sensitizers leads to
Nrf2 activation. Different patterns of cysteine modification of Keap1 show distinct
biological outputs [51, 53]. The magnitude of the activation was correlated with their
sensitizing potency [18].
There are three different types of inhibition of activity. The first type of inhibition is
competitive inhibition. That means the ester compounds metabolized by the same
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carboxylesterases and causes the hydrolysis rates to vary. The typical example is the
interaction between clopidogrel and oseltamivir. Both of them are substrates of CES1,
but clopidogrel has a higher hydrolysis rate than oseltamivir [34]. Based on that,
oseltamivir has as low as 10% of the normal hydrolysis rate when the same
concentration of clopidogrel is present. Oseltamivir is the prodrug and only the
hydrolysis metabolite has a therapeutic effect with lower toxicity. When oseltamivir is
administered with clopidogrel, the therapeutic outcome is decreased around 90% and
the neurotoxicity is increased [55-57]. Serine enzyme inhibitors are the second type of
CES inhibitors. This type of inhibitors can irreversibly bind and change the active-site
serine residues. Transitional analog inhibitors are the third type of inhibition. They
reversibly interact with the active-site serine residues [34, 58-62].
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4. Functional consequence of carboxylesterase
Carboxylesterases are hydrolytic enzymes and functionally interact with other
metabolic enzymes to clear xenobiotics. The pharmacogenomics of carboxylesterases
is an important issue because CES leads to one of the first steps of the
biotransformation pathway. The metabolites of CES associated with other enzymes
and transporters form complicated networks. Therefore, the variability of CES may
link to the significant clinical outcomes reported [63-67].
Many drugs are metabolized by multiple enzymes such as the carboxylesterases and
cytochrome P450 (CYP) systems. The availability of a drug is usually determined by
hydrolysis, because it happens faster than other reactions. The clinical effect of some
ester prodrugs depends on the competition of hydrolysis by CES and oxidation by
CYP. For example, clopidogrel, an antiplatelet agent, loses its pharmacological
activity by hydrolysis by CES1 [3] but activates by CYP2C19, CYP3A4 and to a
lesser extent, other CYP enzymes (Figure 1.) [35, 68-70]. Around 95% of clopidogrel
undergoes the hydrolysis and only 5% is oxidized to active metabolite [3]. The active
metabolite interacts with the purinergic receptor P2Y, G-protein coupled, 12 (P2Y12
receptor) and partitions them out of lipid rafts [71]. On the other hand, prasugrel,
another antiplatelet agent, has to be metabolized by CES2 then by multiple CYP
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enzymes and becomes finally an active compound [35, 68]. Other antiplatelet agent,
acetylsalicylic acid, is also hydrolyzed by CES. After hydrolyzing it, its hydrolytic
metabolite loses 90% of antiplatelet abilities. The combination of these substrates of
CES enzymes may increase their antiplatelet abilities and cause unexpected clinical
effects. Iirinotecan, anticancer agent, a carboxylic acid ester prodrug, is rapidly
hydrolyzed by CES2 to the active metabolite SN-38 to kill cells. On the hand,
Iirinotecan also undergo metabolism by CYP 3A4. More importantly, the metabolites
have different functionality. Iirinotecan metabolized by CES2 represents the
activation and metabolized by 3A4 represents the inactivation [72] (Figure 1.4).
Beside

the

pharmacological

interactions,

induction

of

CES1

may

have

pathophysiological significance as well. CES1 hydrolyzes many endogenous esters [2,
4, 5]. Hydrolysis of cholesterol esters increases free cholesterol and the synthesis of
bile acids to eliminate excessive cholesterol [4]. On the other hand, the increasing of
hydrolyzing triglycerides and cholesterol esters may increases the synthesis and
secretion of very low density lipoprotein (VLDL) and low density lipoprotein (LDL).
Indeed, high CES1 activity has been shown to facilitate VLDL maturation [10, 73, 74].
Transgenic expression of human CES1 in mice leads to increased secretion of apoB
proteins and plasma triglycerides [10]. Elevated levels of LDL increase the risk of
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developing atherosclerosis [75]. Moreover, young patient treated with phenobarbital,
a CES1 inducer, has been observed to have higher plasma total cholesterol and
low-density-lipoprotein cholesterol [76]. Therefore, excessive induction of CES1
without enhancing bile acid synthesis likely has a detrimental effect.

16

vations of irrinotecan [72].
Figuure 1.3 Mettabolic activ
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ABSTRACT
Carboxylesterase-2 (CES2) and cytochrome P450 3A4 (CYP3A4) are two major drug metabolizing
enzymes that play critical roles in hydrolytic and oxidative biotransformation, respectively.

In many

cases, CES2 and CYP3A4 share substrates such as the anticancer prodrug irinotecan and present opposite
outcomes in terms of therapeutic activity. CES2 and CYP3A4 are both expressed in the liver and the
gastrointestinal (GI) tract. The present study was conducted to determine whether CES2 and CYP3A4 are
expressed under developmental regulation and whether the regulation occurs in an organ-dependent
manner. Liver and duodenal tissues were collected from various ages. The liver tissues were divided into
5 age groups: I (1-31 days), II (35-70 days), III (89-119 days), IV (123-198) and IV (≥ 18 years of age).
The duodenal tissues were divided into 4 groups: D1 (1-70 days), D2 (76-141 days), D3 (163-332 days)
and D4 (≥ 18 years). In addition, multi-sampling (liver, duodenum and jejunum) was performed in some
donors. The expression was determined at mRNA and protein levels. In the liver, the levels of CES2 and
CYP3A4 mRNA exhibited a postnatal surge (group I versus II) by 2.7 and 29 fold, respectively.
CYP3A4 but not CES2 mRNA in certain pediatric groups reached or even exceeded the adult level. The
duodenal samples, on the other hand, showed a gene-specific expression pattern at mRNA level. The
level of CES2 mRNA increased with age but the opposite was true with CYP3A4 mRNA. The levels of
CES2 and CYP3A4 protein, on the other hand, increased with age in both liver and duodenum.

The

multi-sampling study demonstrated significant correlation of CES2 expression between the duodenum
and jejunum.
CES2.

However, neither duodenal nor jejunal expression correlated with hepatic expression of

These findings establish that developmental regulation occurs in a gene and organ-dependent

manner.
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1. INTRODUCTION
Personalized medicine is an ultimate goal of health professionals and inter-individual variability presents
the major challenge to achieve this goal [1-4]. While many factors are contributing to inter-individual
variability, biotransformation is recognized as one of the major contributing factors [3, 4].

There are

three types of biotransformation, commonly referred to as phase I [5], phase II [6] and phase III reactions
[7].

Phase I and II reactions are accomplished by drug-metabolizing enzymes.

Phase III reactions,

without chemical modifications, are accomplished by drug transporters. The human genome contains
~150 biotransformation genes with known pharmacological and toxicological significance [3-7]. Many
biotransformation genes are expressed in a wide range of organs and tissues. However, the highest
expression of many biotransformation genes occurs in the liver and the gastrointestinal (GI) tract [8, 9].
The expression of these genes, on the other hand, exhibits large inter-individual variability, up to 100-fold
in some cases [10]. Genetic and environmental factors as well as disease status are known to regulate the
expression of these genes [11-13].

We and investigators have shown that the expression of biotransformation genes is developmentally
regulated in rodents and humans [14-18]. Based on immunoblotting analysis [16], one to two week old
rats express no hydrolase A or B, two major rat carboxylesterases. Consistent with little expression of
carboxylesterases, the intrinsic hydrolytic clearance of the pyrethroid deltamethrin in 10-day old rats is
only ~3% of adult rats [19]. Even in 4-week old rats, the intrinsic clearance is less than half of that of
adults [19].

In addition, young animals are generally much more sensitive to pesticides such as

organophosphates and pyrethroids [20, 21].

Carboxylesterases are known to protect against these

chemicals by hydrolysis in the case of pyrethroids or scavenging mechanism in the case of
organophosphates. Human carboxylesterase-1 (CES-1) and 2 (CES2) in the liver are developmentally
regulated [15, 22, 23].
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We recently showed that the developmental regulation of CES1 in the liver consists of a postnatal surge
followed by an incremental increase throughout the entire adolescence [15, 22]. Based on the level of
CES1 mRNA, the postnatal surge of CES1 is completed two months after birth [22]. The present study
was undertaken to determine whether the ontogenic expression pattern of CES1 represents a common
phenomenon among biotransformation genes. This study focused on CES2 and cytochrome P450 3A4
(CYP3A4). CES2 and CES1 together represent as much as 90% of hydrolytic capacity toward drugs and
other xenobiotics [24, 25]. CYP3A4 is a member of the cytochrome P450 mixed-function oxidase system
[26]. This oxidase is involved in the metabolism of more than 50% drugs and other xenobiotics. CES2
and CYP3A4 are functionally linked in terms of tissue distribution and coupled metabolism.

For

example, both CES2 and CYP3A4 are abundantly expressed in the liver and the GI tract [8, 27, 28].
Importantly, some drugs are metabolized by both CES2 and CYP3A4.

Their relative activity has

profound therapeutic consequences [29]. The anticancer drug irinotecan, for example, is hydrolyzed to
produce SN-38, a metabolite with potent anticancer activity. In contrast, irinotecan undergoes oxidation
by CYP3A4 to produce two major oxidative metabolites: NPC (7-ethyl-10-(4-amino-1-piperidino)
carbonyloxycamptothecin

and

APC

(7-ethyl-10-[4-N-(5-aminopentanoic

acid)-1-piperidino]

carbonyloxycamptothecin. Both NPC and APC are less active than the parent compounds [29].

This study tested a large number of human liver and duodenal samples for the expression of CES2 and
CYP3A4 by Western blotting and reverse transcription-quantitative polymerase chain reaction (RTqPCR). In the liver, the levels of CES2 and CYP3A4 mRNA exhibited a postnatal surge (group I versus
II) by 2.7 and 29 fold, respectively. The duodenal samples, on the other hand, showed a gene-specific
expression pattern at mRNA level. CES2 mRNA increased with age but the opposite was true with
CYP3A4 mRNA.

Nevertheless, CES2 and CYP3A4 protein increased with age in both liver and

duodenum. The multi-sampling study demonstrated significant correlation of CES2 expression between
the duodenum and jejunum. However, neither duodenal nor jejunal expression correlated with hepatic
expression of CES2.
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2. MATERIALS AND METHODS
2.1. Chemicals and supplies
Ponceau S was purchased from Sigma (St. Louis, MO). TaqMan probes were from Life Technologies
Corporation (Grand Island, NY).

The TaqMan assay identification numbers were: CES2,

Hs00187279_m1 (NM_198061); CYP3A4, Hs00604506_m1 (NM_017460.3); and polymerase (RNA) II,
Hs01108291_m1 (NM_000937).

Random primers and M-MLV reverse transcriptase were purchased

from Promega Corporation (Madison, WI). The RNAzol B reagent was from Tel-Test Inc (Friendswood,
TX).

Antibody against glyceradehyde-3-phosphate dehydrogenase (GAPDH) was from Abcam

(Cambridge, MA). Unless otherwise specified, all other reagents were purchased from Fisher Scientific
(Pittsburgh, PA).

2.2. Preparation of RNA and S9 fractions
A total of 102 tissue samples were used in this study including 59 liver, 33 duodenal and 10 jejunal
samples. Multi-sampling was performed in 10 donors, thus, there was a total of 92 donors. Among them,
69 were pediatric (1-332 days of age) and 23 adult donors.

Majority of the donors (54%) were

Caucasian-American. The tissues were acquired primarily from the University of Maryland Brain and
Tissue Bank for Developmental Disorders (Baltimore, MD). Total RNA was isolated with RNAzol B and
the integrity was verified by agarose gel electrophoresis described previously [30].

S9 fractions were

prepared by differential centrifugation as described previously [30]. The use of the human samples was
approved by the Institutional Review Board.

2.3. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)
Total RNA (0.1 μg) was subjected to the synthesis of the first strand cDNA in a total volume of 25 μL
with random primers and M-MLV reverse transcriptase [15]. The reactions were conducted at 25°C for
10 min, 42°C for 50 min and 70°C for 10 min. The cDNAs were then diluted 6 fold and qPCR was
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performed with TaqMan Gene Expression Assay as described previously [15, 23].

The PCR amplifi-

cation was conducted in a total volume of 20 µl containing universal PCR master mixture (10 µl), genespecific TaqMan assay mixture (1 µl), and cDNA template (3 µl). The cycling profile was 50°C for 2
min, 95°C for 10 min, followed by 40 cycles of 15 s at 95°C and 1 min at 60 °C, as recommended by the
manufacturer. Amplification and quantification were done with the Applied Biosystems 7900HT RealTime PCR System.

All samples were analyzed in triplicate and the signals were normalized to

polymerase (RNA) II and then expressed as relative levels of mRNA….

2.4 Western analysis
S9 fractions (8-20 μg) were resolved by 7.5% SDS-PAGE in a mini-gel apparatus and transferred
electrophoretically to nitrocellulose membranes. In some cases, membranes were rinsed once in TBST
buffer (20 mM Tris-HCl, 150 mM NaCl and 0.05% Tween 20) and then blocked in 5 % non-fat milk as
described previously [24, 31]. In other cases, membranes were washed once in 0.1% acetic acid solution
and stained in 0.1% Ponceau S solution for 5 min. The membranes were then washed twice in 5% acetic
acid solution and then blocked in 5 % non-fat milk. The blots were incubated with an antibody against
CES2, CYP3A4 and GAPDH, respectively. The preparation of the antibodies against CES2 and CYP3A4
was described elsewhere [32]. In both cases, the antigens were peptides conjugated with keyhole limpet
hemocyanin. The sequence of CES2 peptide was H2N-CQELEEPEERHTEL-COOH, and of CYP3A4
was H2N-CVKRMKESRLEDTQKHRVDFLQ-COOH. The primary antibodies were subsequently
localized with goat anti-rabbit IgG conjugated with horseradish peroxidase, and horseradish peroxidase
activity was detected with a chemiluminescent kit (SuperSignal West Pico).

The chemiluminescent

signals signal was captured by Carestream 2200 PRO imager.

2.5. Other analyses
Protein concentrations were determined with BCA assay (Pierce) based on bovine serum albumin
standard. Data are presented as mean ± SD. All enzymatic assays were repeated three times with the

39

same microsomal preparation.

Statistical analyses were performed with SPSS-PASW Statistics 20.

Significant differences were tested according to Spearman for correlation or One-way ANOVA followed by
a DUNCAN’s test for comparison of means.

In all cases, significant differences were made when p

values were less than 0.05.
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3. RESULTS
3.1. Expression of CES2 and CYP3A4 mRNA as a function of age
We have shown that the expression of CES1 exhibits a two-phase developmental regulation: a fast surge
in the early period after birth followed by an incremental phase toward the end of adolescence [15, 23].
This study was undertaken to determine whether the two-phase developmental regulation represents a
common phenomenon among drug-metabolizing enzymes. This study focused on CES2 and CYP3A4,
two major drug-metabolizing enzymes [24-26]. CES2 and CYP3A4 share many substrates with different
clinical consequences [29]. We initially tested a large number of individual liver tissues collected at birth
to 198 days of age. Samples were divided into several groups: I (1-31 days), II (35-70 days), III (89-119
days) and IV (123-198 days). As a control, adult livers (i.e., group V) were included. Each group had 1014 individual samples. Among them, 33 were male and 26 female donors (Table I).

The expression of CES2 and CYP3A4 was determined by RT-qPCR with a Taqman probe and Western
blotting. As shown in Fig. 1 and Table II, the relative level of CES2 mRNA in group I-V was 26, 70, 88,
80 and 100%, respectively. The level of CYP3A4 mRNA in these groups was 2, 65, 110, 98 and 100%,
respectively. Clearly, both genes exhibited a postnatal surge (group I versus II) with a magnitude of 2.7
and 29 fold, respectively. For CES2 mRNA, none of the postnatal groups reached the adult level. In
contrast, the level of CYP3A4 mRNA in groups III and IV reached or even exceeded the adult level (Fig.
1, Table II). The levels of the corresponding proteins, on the other hand, showed a better age-dependent
increase for both enzymes (Fig. 1).

The expression of mRNA for both genes exhibited large inter-

individual variations with CYP3A4 mRNA being much greater (Fig. 1, Table I).

3.2. Correlation of ontogenic expression between hepatic CES2 and CYP3A4
Both CES2 and CYP3A4 mRNA exhibited a postnatal surge, however, the magnitude differed markedly
(Fig. I and Table II). In addition, the level of CYP3A4 but not CES2 mRNA in certain pediatric groups
reached or even exceeded the adult level. These observations pointed to potential differences in the
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molecular mechanisms supporting the ontogenic regulation of these two genes.

To shed light on this

possibility, correlation studies were performed on age as well as on each other. As shown in Fig. 2A, the
level of CES2 mRNA was significantly correlated with age and the correlation was slightly better during
the period of 1-70 days of age (r = 0.359) than that of 0-198 days (r = 0.478). Similar trend of correlation
was detected on the level of CYP3A4 mRNA over age (r = 0.350 versus r =0.539). Importantly, the
levels of CES2 and CYP3A4 mRNA were correlated well. The correlation coefficient for the period of 0198 days was 0.318 and the correlation was much improved for the period of 1-70 days (r = 0.859),
suggesting that the same or similar mechanism support the ontogenic expression of CES2 and CYP3A4,
particularly during the first two months after birth.

3.3. Duodenal expression of CES2 and CYP3A4
In addition to the liver, the GI track expresses high levels of drug metabolizing enzymes [24-26]. We
next tested whether the duodenum shares with the liver in the ontogenic expression of CES2 and
CYP3A4. A total of 43 duodenal samples were collected and divided into I (1-70 days), II (76-141 days),
III (163-332 days) and IV (≥ 18 years) (Table III) with each group having 9-13 individual samples. E As
shown in Fig. 3A (Left), the levels of CES2 mRNA and protein exhibited age-related increases in groups I,
II and III (Fig. 3, Table III), although the increase in CES2 mRNA between group III and IV was
minimal (Table III). The adult group, nevertheless, exhibited much greater individual variation in CES2
mRNA (Left of Fig. 3A). Ponceau S staining was used for the normalization of loading and transfer as
the levels of several commonly used house-keeping proteins (e.g., GAPDH) showed large group-group
variations.

The correlation of CES2 mRNA with age among the duodenal samples (0-332 days) was

statistically significant (p < 0.017) and the correlation coefficient was 0.412 (Fig. 3A). Interestingly, the
correlation among the 0-96 day samples had a smaller coefficient (r = 0.283) and did not reach statistical
significance. Overall, the correlation study demonstrated that CES2 mRNA exhibited a similar pattern of
ontogenic expression in the liver and duodenum.
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In contrast to the liver, CYP3A4 mRNA in the duodenum exhibited a major difference in the age-related
expression. The level of CYP3A4 mRNA in the liver was correlated positively with age (Fig. 1, Table
II).

However, the level of CYP3A4 mRNA decreased with age (Left of Fig. 3B, Table IV).

In the

duodenal samples, a 25% decrease of CYP3A4 mRNA was detected from group I (1-70 days) to groups II
(76-141 days) or III (163- 332 days). Overall, the level of CYP3A4 mRNA in the duodenal samples
among pediatric donors was inversely correlated with age, although the inversed correlation did not reach
the level of statistical significance (r = -0.145, p = 0.421). Interestingly, during the first three months
after birth (1-96 days), the level of CYP3A4 mRNA showed a trend of positive correlation with age (r =
0.184, p = 0.546) (Fig. 3B).

Nevertheless, none of the correlation coefficients reached statistical

significance. Among all duodenal samples, large individual variations were detected with coefficients of
variance ranging from 1.78 to 2.46 (Table IV).

The adult duodenal samples, compared with group I

sample, showed a 67% decrease in CYP3A4 mRNA (Left of Fig. 3B).

Interestingly, the level of

CYP3A4 protein in this group was much higher than that of all other duodenal groups (pediatric donors).

3.4. Organ-specific ontogenic expression of CES2
The studies with groups-based samples demonstrated large individual variations, although the variations
tended to be smaller with the liver samples (Figs. 1 and 3). To minimize potential individual variations,
we next determined the expression of CES2 in the liver and intestinal samples from the same donors.
This was of significance as this study would specify whether individuals expressing relatively high levels
of CES2 in the liver also express high levels of this enzyme in his/her GI track.

We collected liver,

duodenum and jejunum from 10 individuals. With an exception of a single adult donor, all donors were
pediatric from 1 to 196 days of age. Once again, both RT-qPCR and Western blotting were used for the
expression determination. CES2 mRNA but not for CES2 protein was detected in all samples. While
there were exceptions, the relative abundance of CES2 protein occurred in an order of the liver, the
duodenum and the jejunum (Fig. 3A). Donor 10, on the other hand, expressed the highest level of CES2
protein in the duodenum. Donor 3 expressed comparable levels of CES2 protein among all three organs
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and donor 4 did not express detectable CES2 protein in either organ. Based on the level of CES2 rnRNA，
duodenal and jejunal exp 自 ssion was significantly correlated with a coefficient of 0 .359 (p 0.023)
However neither duodenal nor jejunal exp 自 ssion was correlated liver expression (Fig. 4B)
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4. DISCUSSION
Individualized medicine is an ultimate goal of health professionals and inter-individual variability
presents the major challenge for individualized medicine [1-4].
contributor to individual variability [3, 4].

Biotransformation is the major

In adults, the expression of drug-metabolizing enzymes is

regulated largely by environmental factors, whereas in children, environmental and developmental factors
are both involved in the regulatory process [15, 23]. We have recently made a concerted effort and laid
groundwork on the ontogenic expression of biotransformation genes.

In this study, we tested a large

number of liver and small intestinal samples from pediatric donors for the expression of CES2 and
CYP3A4, two major drug-metabolizing enzymes [24, 26].

While both genes were developmentally

regulated, the overall outcomes varied depending on a gene and an organ. In the case of CES2, agedependent increases were detected in the liver and the GI tract at both mRNA and protein levels (Figs. 1
and 2). However, the age-related increases in CYP3A4 were detected at protein in both organs but not
mRNA (Figs. 1 and 2).

The results described in this study, nevertheless, point to an important conclusion about ontogenic
expression in human liver. Namely, the postnatal surge, although exceptions may exist, is a general
phenomenon among biotransformation genes.

The magnitude of the surge, on the other hand, varied

depending on a gene. Based on RT-qPCR analysis, the level of CYP3A4 mRNA showed a surge by 29fold, but the level of CES2 mRNA by 2.7 fold only (Fig. 1). We previously reported a 7.1-fold postnatal
surge of CES1 mRNA. The surge of CES2 and CYP3A4 mRNA represented 65-70% of the level in adult
liver, whereas in the case of CES1, it represented 50% only [23]. Following the surge was gradual
increases in mRNA expression during the 6 months after birth. However, such increases varied markedly
from a gene to another. In the case of CES2, 10-20% increases were detected from 70 to 198 days of age,
but the level of CES1 mRNA was increased by only 5% during this period.

The level of CYP3A4

mRNA, on the other hand, was increased by as much as 45%. As a matter of fact, the level of CYP3A4
mRNA in groups III (89-119 days) and IV (123-198 days) reached or even exceeded the adult level (Fig.
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1). In contrast, the surge of CES2 mRNA was followed by an incremental increase toward adulthood,
which was similar to that of CES1 mRNA. However, the incremental phase of CES2 mRNA represented
less percentage than that of CES1 (20 vs. 50%) (23, Fig. 1).

The level of CYP3A4 but not CES2 mRNA displayed organ-specific ontogenic expression patterns. The
hepatic expression of CYP3A4 mRNA, like CES2 mRNA, was correlated significantly during the first six
months of life (r = 0.350, p = 0.027) (Left of Fig. 2B). Similarly to CES2 mRNA, CYP3A4 mRNA was
correlated much better with age (r = 0.539, p < 0.014) when the period of the first 70 days was considered
(Right of Figs. 2A and B).

Importantly, levels of CES2 and CYP3A4 mRNA were correlated

significantly with each other (Fig. 2C).

These findings suggested that CES2 and CYP3A4 share

mechanisms in ontogenic expression, at least in light of hepatic mRNA expression. In contrast, the
duodenum exhibited different expression patterns between CES2 and CYP3A4 mRNA.

A positive

correlation during the first 70 days was detected for both genes (Right of Fig. 3). However, the overall
correlation during the first 198 days was opposite. The abundance of CYP3A4 mRNA was negatively
correlated with age, while the level of CES2 mRNA positively with age in the duodenum (Fig. 3).

The multi-organ sampling study provided important information on inter-organ differences in terms of
gene expression. While the level of CES2 mRNA increased with age in both liver and duodenum, hepatic
and duodenal levels from the same donors showed insignificant correlation (Fig. 4B). On the other hand,
duodenal and jejunal levels of CES2 mRNA were significantly correlated (Fig. 4B). The insignificant
correlation between the liver and small intestine suggests that the developmental regulation is mediated
by different triggers in these two organs. The precise mechanisms remain to be determined, and many
changes take place immediately after birth and in the early days/weeks of life, notably on hormones and
food intake. On the other hand, many biotransformation genes are expressed in a rapid increasing manner
such as CYP3A4 and CES1. For example, fibroblast growth factor-21 (FGF-21) is induced rapidly [33],
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and importantly the induction of FGF-21 was diminished in mice lacking functional peroxisome
proliferator-activated receptor-α (PPARα) [33].

It happens that this receptor has been implicated in the regulation of the expression of carboxylesterases
in rodents [16, 34, 35], although its involvement in the regulated expression of human carboxylesterases
remains to be established. On the other hand, the CES2 promoter region contains two PPARα putative
elements located -907 and -256, respectively [36].

It has been reported that the CES2 gene has three

promoters, designated promoter-1, promoter-2 and promoter-3, respectively.
different transcription start sites, thus producing distinct transcripts.

These promoters use

It appears that promoter-3 has a

broad tissue activity and supports constitutive but low level of expression. In contrast, promoter 1 and
promoter 2 show tissue-dependent activity.

For example, promoter 1 is more active in the liver than

promoter 2, and the opposite is true in the small intestine [36]. Interestingly, one of the PPARα putative
elements is present in promoter 1 and the other in promoter 2. Given the observation that the liver but not
small intestine expresses high levels of PPARα [37, 38], the element in promoter 1 is likely involved in
the developmental regulation of CES2 in the liver. On the other hand, PPARδ and PPARγ are expressed
much higher in the GI track. Therefore, these two receptors likely play a role in the developmental
regulation of CES2 in the GI tract [37]. While all PPARs are functionally related, they exhibit different
ligand specificity [38].

An involvement of different PPARs in the developmental regulation of CES2

between the GI and liver provides an explanation to the insignificant correlation on CES2 expression
between these two organs, although both organs exhibited significant age-dependent expression (Figs. 1,
2 and 3).

In contrast to RT-qPCR, Western blotting consistently detected age-related increases regardless of genes
(CES2 or CYP3A4) or organs (liver and duodenum) (Figs. 1 and 3). The precise mechanisms remain to
be determined on the disproportions between mRNA and protein expression of CES2 and CYP3A4. In
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particular, duodenal samples in the adult group had the lowest CYP3A4 mRNA, but the same group
expressed the highest level of CYP3A4 protein (Left of Fig. 3B).
efficiency of intestinal CYP3A4 mRNA increases with age.

It is likely that the translational

Alternatively, the expression of certain

microRNAs (miRs) that target CYP3A4 transcript increases and thus negatively affects the production of
CYP3A4 proteins.

In support of this possibility, several miRs have been reported to regulate the

expression of CYP3A4 [39] or the pregnane X receptor, a major regulator of CYP3A4 expression in
response to xenobiotic stimuli [40]. Nevertheless, it remains to be determined whether these miRs are
expressed in an age-dependent manner.

The precise pharmacological significance of the organ-specific expression remains to be established. In
the case of CES2, the contribution to the overall hydrolysis between the liver and GI is likely closer than
the difference in the expression. In this study, the entire wall of the small intestine was used. It is not
clear whether CES2 is present in the whole section of the wall or primarily in the mucosal layer. Based
on the study in the puppies [41], the mucosal layer takes 60-70% of the thickness of the entire wall.
Therefore, the expression levels were probably underestimated if CES2 is exclusively present in the
mucosal layer. Likewise, the presence of CES2 in the liver may not be uniform. We previously showed
that several rat carboxylesterases were primarily located in the centrilobular regions [42, 43]. Finally, the
initial concentrations of drugs and other xenobiotics in the small intestine are much higher than those in
the liver after oral administration. Therefore, it is likely that the GI track contributes much greater to the
overall hydrolysis than the levels expression.

In summary, our work points to several important conclusions. First, the postnatal surge of mRNA
expression in the liver, although exceptions may exist, is a general phenomenon among biotransformation
genes.

Second, high-levels of mRNA do not necessarily result in high-levels of protein, and such

disproportions likely occur in an organ-specific manner. And third, individuals may disproportional drug-
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metabolizing capacities between the liver and the GI tract, two major biotransformation organs. These
findings establish that developmental regulation occurs in a gene and organ-dependent manner.
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Table I. Demographic distribution of liver donors
Group

n

Male/Female

CA

AA

H

I (1-31 days)

12

6/6

6

4

2

II (35-70 days)

13

5/8

5

8

III (89-119 days)

10

7/3

4

6

IV (123-198 days)

10

8/2

4

5

V (≥18 years)

14

7/7

10

4

Abbreviation: CA, Caucasian-American; AA, African American; H, Hispanic
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1

Table II. Relative levels of liver CES2 and CYP3A4 mRNA in various age groups
Group

CES2 mRNA

CYP3A4 mRNA

I (1-31 days)

2.07 (1.57)

1.33 (1.79)

II (35-70 days)

5.57 (3.45)

38.6 (34.4)

III (89-119 days)

6.99 (2.63)

65.6 (101.8)

IV (123-198 days)

6.36 (1.56)

58.6 (75.6)

V (≥18 years)

7.96 (3.81)

59.7 (69.7)

Note Data presented as mean ± SD (parenthesis)
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Table I. Demographic distribution of duodenal donors
Group

n

Male/Female

CA

AA

I (1-70 days)

11

3/8

6

5

II (76-141 days)

9

7/2

3

6

III (163-332 days)

13

9/4

7

6

V (≥18 years)

10

5/5

8

2

Abbreviation: CA, Caucasian-American; AA, African American; H, Hispanic

58

H

Table IV. Relative levels of duodenal CES2 and CYP3A4 mRNA in various age groups
Group

CES2 mRNA

CYP3A4 mRNA

I (1-70 days)

2.71 (2.98)

19.7 (35.2)

II (76-141 days)

3.42 (4.57)

14.2 (29.4)

III (163-332 days)

6.33 (4.23)

15.3 (37.7)

V (≥18 years)

6.62 (12.01)

6.61 (15.8)

Note Data presented as mean ± SD (parenthesis)
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LEGENDS FOR FIGURES
Fig. 1. Hepatic expression of CES2 and CYP3A4 as a function of age Total RNAs from livers were
subjected to RT-qPCR analysis for the levels of CES2 or CYP3A4 mRNA by Taqman probe as described
in the section of Materials and Methods. The signals from each target were normalized based on the
signal from Pol II and expressed as relative levels among all samples. The data are presented as mean ±
SD. For Western analysis S9 fractions (7.5 μg for CES2 and 10 μg for CYP3A4) were resolved by 7.5%
SDS-PAGE and transferred electrophoretically to nitrocellulose membranes. The samples were pooled
with the same amounts of proteins from individual samples in the same group. The blots were incubated
with an antibody against CES2, CYP3A4 or GAPDH and developed with chemiluminescent substrate.
The signal was captured by Carestream 2200 PRO imager. *Statistical significance at p < 0.05.

Fig. 2. Correlation analyses between age and levels of CES2 or CYP3A4 mRNA The correlation was
performed with SPSS Statistics 20.

(A) Correlation of CES2 mRNA as a function of age:1-198 days

(Left) or 1-70 days (Right). (B) Correlation of CYP3A4 mRNA as a function of age:1-198 days (Left) or
1-70 days (Right). (C) Correlation of CES2 over CYP3A4 mRNA as a function of age:1-198 days (Left)
or 1-70 days (Right). Correlation coefficients and corresponding p values are shown.

Fig. 3. Duodenal expression of CES2 and CYP3A4 as a function of age and correlation analyses (A)
Duodenal expression of CES2 Total RNAs from duodena were subjected to RT-qPCR analysis for the
levels of CES2 mRNA by Taqman probe and the signals from each target were normalized based on the
signal from Pol II and expressed as relative levels among all samples. The data are presented as mean ±
SD.

For Western analysis S9 fractions (10 μg) were resolved by 7.5% SDS-PAGE and transferred

electrophoretically to nitrocellulose membranes. The blot was stained by 0.1% Ponceau S as described in
the section of Materials and Methods. Thereafter the blot was incubated with an antibody against CES2
or GAPDH and developed with chemiluminescent substrate. The signal was captured by Carestream
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2200 PRO imager. Once again, the correlation of CES2 mRNA as a function of age was performed with
SPSS Statistics 20.

(B) Duodenal expression of CYP3A4 All procedures for the expression and

correlation analysis for CYP3A4 were the same as described above. However, the Western blotting used
20 μg of S9 fractions. *Statistical significance at p < 0.05.

Fig. 4. Multi-sampling study on the expression of CES2 Liver, duodenal and jejunal S9 fractions (8
μg) were resolved by 7.5% SDS-PAGE and transferred electrophoretically to nitrocellulose membranes.
The blots were stained by 0.1% Ponceau S and then incubated with an antibody against CES2 or GAPDH
and developed with chemiluminescent substrate.
imager.

The signal was captured by Carestream 2200 PRO

Once again, the correlation of CES2 mRNA between duodenum and jejunum (Left) or liver

jejunum was performed (Right) with SPSS Statistics 20. Correlation coefficients and corresponding p
values are shown.
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ABSTRACT
Aims Carboxylesterase-1 (CES1), the most versatile human carboxylesterase, plays critical
roles in drug metabolism and lipid mobilization. This enzyme is highly induced by antioxidants
and sensitizers. These compounds are known to activate nuclear factor-E2 related factor-2
(Nrf2) by reacting to kelch-like ECH-associated protein-1 (Keap1). The aims of this study were
to determine whether antioxidant sulforaphane (SFN) and sensitizer trinitrobenzene sulfonate
(TNBS) target Keap1 similarly and whether they use the same element for CES1 induction.
Results Two elements (S/ARE and ARE4) were identified to support Nrf2 in the regulated
expression of CES1A1. Both elements were bound by Nrf2, however, the S/ARE element
supported whereas the ARE4 element repressed the transactivation of Nrf2. The repression
required higher amounts of Nrf2.

SFN promoted intramolecular oxidation whereas TNBS

promoted intermolecular oxidation of Keap1.
Innovation This study reports an Nrf2 repressive element although this transcription factor
generally confers transactivation activity.

SFN and TNBS, both activating the Keap1-Nrf2

pathway, react differently to Keap1.
Conclusion Both positive and negative Nrf2 elements exist even within the same gene.
Common activators of Nrf2 may differ in the molecular recognition of Keap1. High levels of
CES1 are linked to lipid retention. Excessive induction of CES1 by antioxidants and sensitizers
likely provides a mechanism for potential detrimental effect on human health.
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INTRODUCTION
Carboxylesterases (CES, E.C.3.1.1.1) constitute a large class of enzymes that play important
roles in drug metabolism and lipid mobilization [1-4].

In the human genome, seven

carboxylesterase genes are identified [1]. However, only three are catalytically characterized
including CES1, CES2 and CES3 [5]. CES1 is encoded by two distinct genes: CES1A1 and
CES1A2 [1], but CES1A1 is normally expressed to a greater extent [6]. CES1 is the most
versatile human carboxylesterase and catalyzes hydrolytic, synthetic and transactivation
reactions. While all carboxylesterases are found to play roles in drug metabolism, emerging
evidence links the sustained high-level expression of CES1 to the increased risk of developing
cardiovascular diseases, obesity and insulin resistance [7-9].

Antioxidants and skin sensitizers are two types of compounds recently shown to induce CES1
[10-13]. Some sensitizers induced CES1 by as many as 20 fold [111]. The precise mechanism
on the sensitizer-induction remains to be established. The induction of CES1 by antioxidants,
on the other hand, is mediated by Nrf2 (nuclear factor-E2 related factor-2) [14].

This

transcription factor recognizes antioxidant response element (ARE) and confers potent
transactivation [15]. RNA interference against Nrf2 abolished CES1 induction by antioxidants
[14]. However, a native promoter reporter containing putative AREs was repressed by Nrf2 [14].
Majority of skin sensitizers, on the other hand, are sulfhydryl reactive agents and shown to react
with kelch-like ECH-associated protein-1 (Keap1) [10, 13], an inhibitor of Nrf2. Interaction with
Keap1 by sensitizers leads to Nrf2 activation. The magnitude of the activation was correlated
with their sensitizing potency [10].

The present study was performed to test the hypothesis that both antioxidants and sensitizers
react to Keap1 and causes transactivation of CES1A1 via a novel Nrf2 element. To test this
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hypothesis, Keap1-transfected cells were treated with sensitizer trinitrobenzene sulfonate
(TNBS) or antioxidant DL-sulforaphane (SFN) and various molecular species of Keap1 were
determined. In contrary to the hypothesis, SFN promoted intramolecular oxidation whereas
TNBS promoted intermolecular oxidation of Keap1.

To locate the element supporting the

transactivation, the regulatory sequence of the CES1A1 gene was dissected and tested for the
responsiveness to TNBS, SFN or Nrf2. Two elements were identified and designated as S/ARE
(sensitizing/antioxidant response element) and ARE4, respectively. Interestingly, the S/ARE
element supported Nrf2 transactivation whereas the ARE4 repressed it although the S/ARE
element was a more sensitive target of Nrf2.
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RESULTS
CES1 induction by SFN and TNBS in primary cultures and cell lines
Humans are exposed to antioxidants and sensitizers primarily through the gastrointestinal track
and skin. We first confirmed whether CES1 is induced by SFN and TNBS in primary cultures
and cell lines from these organs. Cells were treated with SFN or TNBS and CES1 expression
was determined initially by RT-qPCR with a Taqman probe.

This probe recognizes both

CES1A1 and CES1A2 mRNA. In addition, the mRNA level of NAD(P)H:quinone oxidoreductase
(NQO1), an Nrf2 target gene [16], was determined as well. As summarized in Fig. 1, both SFN
and TNBS significantly increased CES1 and NQO1 mRNA. The highest induction of CES1
mRNA was 3.9 fold and occurred in Huh7 cells treated with SFN (Fig. 1D) and the least (1.6 fold)
in primary hepatocytes treated with TNBS (Fig. 1C). In contrast, the highest induction of NQO1
mRNA was 5.7 fold and occurred in primary hepatocytes (Fig. 1C), the least (1.9 fold) in primary
fibroblasts treated with SFN (Fig. 1A). Except for HT1080 cells, SFN caused greater induction
of CES1 than TNBS, and NQO1 mRNA was induced to a greater or comparable extent by
TNBS (Fig. 1). In HT1080 cells, TNBS caused slightly higher induction of CES1 mRNA than
SFN but the opposite was true on NQO1 induction (Fig. 1B). Both SFN and TNBS markedly
increased CES1 protein (Fig. 1E).

Stimulation of the CES1A1 promoter by SFN, TNBS and Nrf2
Nrf2 was implicated in the induction of CES1A1 by antioxidants including SFN [14], and many
sensitizers are potent activators of Nrf2 [13]. We next tested whether TNBS and SFN induce
CES1A1 via the same Nrf2 element. Reporters were prepared to contain the CES1A1 promoter
and upstream sequence at varying length. As shown in Fig. 2A (Middle), reporters containing
upstream sequence of 3582 bp (i.e., -3582) or further responded to both SFN and TNBS. The
CES1A1-3582-Luc reporter was activated the most (Fig. 2A). In contrast, the other reporters,
containing shorter sequence than the CES1A1-3582-Luc reporter, were suppressed by both
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chemicals, and the suppression was greater on CES1A1-3432-Luc and CES1A1-2293-Luc than
CES1A1-1426-Luc (Middle of Fig. 2A).

Next we tested whether these reporters show a similar pattern of response to Nrf2. Huh7 cells
were transfected with a reporter, along with Nrf2 or the vector. Consistent with the results on
the TNBS and SFN treatment, the sequence from -3582 to -3432 was identified to support Nrf2transactivation (Fig. 2A, Right).

Likewise, the CES1A1-3432-Luc and CES1A1-2293-Luc

reporters were repressed by Nrf2 (Right of Fig. 2A).

To further narrow down the sequence

supporting the action of Nrf2, deletions of the CES1A1-3582-Luc reporter were made from the 5’
end and the resultant reporters were tested for the lost responsiveness to Nrf2. As shown in Fig.
2B, the reporter 1A1-3492-Luc but not 1A1-3482-Luc was transactivated by Nrf2. Actually, the
1A1-3482-Luc reporter was repressed by Nrf2.

These findings suggest that the 10-base

sequence from -3492 to -3482 was critical for Nrf2-transactivation.

Characterization of the S/ARE element
The study with deletion mutants suggested that this 10-base sequence contains or is part of the
Nrf2/TNBS/SFN response element: designated the S/ARE element. We next performed a set of
experiments to characterize this element. We first tested whether Nrf2 binds S/ARE element
and whether this binding can be competed by ARE4, an element previously identified to support
Nrf2-transactivation [14]. As shown in Fig. 3A, incubation of a biotin-labeled S/ARE probe with
nuclear extracts from SFN-treated cells produced a shifted band (lane 2).

This band was

eliminated by an Nrf2 antibody (lane 3) and competed by non-labeled S/ARE (lanes 4 and 5),
but not its mutant (lanes 6 and 7). In addition, non-labeled ARE4 element effectively competed
the binding as well (lanes 8 and 9). Nevertheless, this experiment demonstrated that both the
S/ARE and ARE4 were bound by Nrf2.

We next tested whether the S/ARE-containing

sequence is intracellularly occupied by Nrf2.
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antibody and the precipitated DNA was detected for the enriched S/ARE- or ARE4-fragment.
As shown in Fig. 3B, comparable amplifications were detected with the input on both S/AREand ARE4-fragments, however, the ChIPed DNA produced robust amplification of the S/AREbut not ARE4- fragment (Fig. 3B). As expected, no amplification was detected with sample
precipitated with pre-immune IgG.

Activation of the S/ARE element reporter by SFN, TNBS and Nrf2
The EMSA and ChIP experiments demonstrated that the S/ARE element serves as a major site
for Nrf2 to interact with the CES1A1 gene. We next tested whether the interaction confers
biological activities. Three reporters were tested including the S/ARE, CES1A1-3582-Luc and
CES1A1-3582m-Luc reporters (Fig. 4A). The CES1A1-3582m-Luc, a mutant of the CES1A13582-Luc, had the S/ARE element replaced with its mutant sequence (Table I). Cotransfection
was performed to test the responsiveness of these reporters to SFN, TNBS and Nrf2. As shown
in Fig. 4B, SFN at 0.5 µM significantly activated the S/ARE reporter and the CES1A1-3582-Luc
(bars labeled with different letters). Higher concentrations caused higher activation of both
reporters except 10 µM on the S/ARE reporter (Fig. 4B). In contrast, none of the concentrations
activated the CES1A1-3582m-Luc reporter.

Actually this mutant reporter was suppressed

somewhat, although the suppression did not reach the level of statistical significance (Fig. 4B).
Similar responding patterns to TNBS were detected (Fig. 4C).

Likewise, Nrf2 increased the

activities of S/ARE and CES1A1-3582-Luc but not CES1A1-3582m-Luc reporter (Fig. 4D).
However, several notable differences were observed (Fig. 4D): (a) Nrf2 caused slightly less
activation of the CES1A1-3582-Luc than the S/ARE reporter, when Nrf2 was assayed at 1-10 ng;
(b) Nrf2 at 20 ng, the highest concentration used, caused less activation of both reporters; and
(c) it was surprising that higher amounts of Nrf2 (10 and 20 ng) significantly repressed the
mutant reporter CES1A1-3582m-Luc (Fig. 4D).
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Activation comparison of S/ARE element with other Nrf2 elements
The EMSA, ChIP and reporter experiments established that the S/ARE element supported
robust responsiveness to SFN, TNBS and Nrf2. Next, we compared the responding potential of
this element with well-characterized Nrf2 elements. Reporters harboring the CES1A1-ARE4
element or the corresponding CES1A2-S/ARE were also included. In addition to Nrf2, these
reporters were tested for their responsiveness to Nrf1, an Nrf2 functionally related protein [17].
For direct comparison, reporters were prepared to contain a single copy of an ARE element. As
shown in Fig. 5, all reporters were transactivated by Nrf1 and Nrf2 except Nrf1 on the NQO1
reporter (Fig. 5F) and Nrf2 on the 1A1-ARE4 reporter (Fig. 5B). In both cases, their activity was
actually decreased, and the decrease was statistically significant in the 1A1-ARE4 reporter (Fig.
5B). With a single exception (i.e., 1A1-ARE4), Nrf2 caused greater activation than Nrf1 on all
reporters tested. The highest transactivation was detected with the CES1A1-S/ARE reporter
(5.8 fold) followed by the CES1A2-S/ARE reporter (5.2 fold). The CES1A2-S/ARE reporter
(Figs. 5A and C), compared with its CES1A2-S/ARE counterpart, was activated to a greater
extent by Nrf1. In some other cases such as the reporter of GCLM (glutamate-cysteine ligase
regulatory subunit), Nrf1 and Nrf2 caused comparable activation (Fig. 5E).

Differential reactivity of SFN and TNBS toward Keap1
In the Keap1-Nrf2 pathway, Keap1 is the initiator whereas Nrf2 is the executor. Keap1 is a
cysteine-rich protein and some of the cysteines serve as reactive targets for antioxidants and
sensitizers. As a result, Keap1 has three forms depending on the oxidative status of cysteines:
reduced Keap1, intramolecular and intermolecular Keap1.

We took advantage of their

differences in electrophoretic mobility and tested whether SFN and TNBS produce similar
composition of these three Keap1 molecular species. Cells were transfected with Keap1 and
treated with SFN or TNBS at various concentrations and the cell lysates were then separated by
non-reducing electrophoresis followed by Western blotting. As shown in Fig. 6A, both SFN and
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TNBS decreased reduced mouse Keap1. Surprisingly they differed in increasing intramolecular
and intermolecular Keap1.

SFN increased intramolecular Keap1 whereas TNBS increased

intermolecular Keap1. Similar changes were detected with human Keap1 (Fig. 5B).
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DISCUSSION
CES1 is the most versatile human carboxylesterase and catalyzes hydrolysis, synthesis and
transesterification [1, 2]. In this study, we reports that TNBS and SFN efficaciously induced
CES1 through Nrf2. Two elements, S/ARE and ARE4, were identified to bind to Nrf2 (Fig. 3A),
however, they exhibited opposite activities. S/ARE supported transactivation whereas ARE4
supported repression of Nrf2, although S/ARE was a more sensitive target (Figs. 4D and 5B).
Actually, the S/ARE reporter was activated the most by Nrf2 among all ARE reporters (Fig. 5).
Compared with all AREs, ARE4 differs by two nucleotides at the 4th and 5th position in the coresequence (Fig. 5H). The ARE4 has GA whereas other AREs have CT in these positions. However, a frequency matrix analysis has predicted that 18% of ARE elements have a G and 6% an
A in the 4th and 5th position, respectively [18], suggesting that this dinucleotide substitution (i.e.,
CTGA) may not be entirely responsible for the observed repression by Nrf2 (Fig. 5B).

It is likely that this GACT substitution works with flanking nucleotides and negatively responds
to Nrf2. Indeed, computer program ALGGEN-PROMO predicts that the ARE4 core-sequence
overlaps with a Yin-Yang1 (YY1) element. This element, CGTGAGACA, consists of 5’ flanking
dinucleotide CG and seven nucleotides of the ARE4 core sequence (in italic) including the
dinucleotide GA discussed above (Fig. 6). Importantly, a recent study has shown that Nrf2
negatively regulated the transcription of the fibrosis transmembrane conductance receptor gene
(CFTR) through an YY1 element overlapped with an ARE (CAAATGACA underlined) [19].
Although the CES1A1 YY1 element shares five nucleotides with the CFTR YY1 element, the
CES1A1 YY1 element lacks the typical core nucleotides of YY1 element [19]. However, these
authors detected YY1-Nrf2 complex [19], suggesting that YY1 and Nrf2 form heterodimers and
bind to an YY1-Nrf2 composite site. On the other hand, Nrf2 has been established to preferably
form heterodimers with small Maf proteins and confer transactivation activity [20, 21], thus
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dominating the repression through the YY1-Nrf2 mechanism [Fig. 6]. In support of this notion,
the repression of CES1A1 reporters was evident when Nrf2 was highly expressed (Fig. 2A), or
in the absence of the S/ARE element (Figs. 3D and 5B). Nevertheless, a confirmation of YY1,
along with Nrf2, in the suppression of CES1 will provide an example of how a very same gene
can be regulated by the same transcription factor with opposite regulatory activity.

Another interesting finding is that SFN and TNBS caused different changes in the overall
conformation of Keap1. SFN promoted thiol oxidation of Keap1 within Keap1 whereas TNBS
promoted the thiol oxidation between two Keap1 molecules (Fig. 5). Thus, TNBS induced the
formation of large Keap1 complex. The precise mechanism on the difference remains to be
determined.

It is likely that TNBS activates the Keap1-Nrf2 pathway by directly reacting

sulfhydryl groups of Keap1, whereas SFN activates it by altering the cellular oxidative potentials.
In support of this possibility, TNBS but not SFN is potent sulfhydryl agent [22, 23]. However, it
remains to be determined whether the different reactivity between SFN and TNBS represents
general difference between antioxidants and skin sensitizers. Nevertheless, majority of skin
sensitizers are sulfhydryl reactive agents [10, 13].

The significance of the induction of CES1 through the Nrf2 pathway remains to be determined.
Carboxylesterases are generally considered detoxification enzymes, therefore, induction of
CES1 likely represents cytoprotective response [1. 5]. On the other hand, induction of CES1
may have pharmacological significance, particularly regarding the metabolism of ester drugs.
For example, the antiplatelet agent clopidogrel undergoes predominant hydrolysis (95%) and
hydrolysis represents inactivation [2]. As a result, exposure to antioxidants or skin sensitizers
may decrease the antiplatelet activity of clopidogrel. In contrast, hydrolysis of oseltamivir, a
widely used anti-influenza agent, represents activation, and only the hydrolytic metabolite exerts
anti-influenza activity [24]. Therefore, induction of CES1 likely leads to increased anti-viral
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activity of oseltamivir. We have shown that the hydrolytic metabolite, compared with the parent
compound oseltamivir, is more cytotoxic [24]. However, the Nrf2-mediated induction of CES1
may cause little changes in the overall toxicity as this pathway has also been found to support
the induction of multidrug resistance protein-4 [25], a transporter that effluxes the hydrolytic
metabolite [26].

In addition to the pharmacological implications, induction of CES1 may have pathophysiological
significance as well. CES1 hydrolyzes many endogenous compounds such as triglycerides and
cholesterol esters [1, 4, 5]. Hydrolysis of cholesterol esters increases free cholesterol, leading
to increased synthesis of bile acids [4].

Secretion of bile acids represents the only net

elimination of excessive cholesterol [27]. On the other hand, increased free fatty acids by
hydrolyzing triglycerides and cholesterol esters likely increase the synthesis and secretion of
very low density lipoprotein (VLDL), a precursor that leads to the formation of low density
lipoprotein (LDL) (28-30).

Indeed, high CES1 activity has been shown to facilitate VLDL

maturation [29]. Transgenic expression of CES1 leads to increased secretion of apoB proteins
and plasma triglycerides [28].
atherosclerosis [31].

Elevated level of LDL increases the risk of developing

Therefore, excessive induction of CES1 without enhancing bile acid

synthesis likely has detrimental effect.
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INNOVATION
Nuclear translocation of Nrf2 is the essential event in the activation of the Keap1-Nrf2 pathway
[32-34].

Normally, Nrf2 is sequestered in the cytoplasm by complexing with Keap1.

The

presence of antioxidants or sensitizers induce conformational changes of Keap1, leading to the
release and nuclear translocation of Nrf2. In this study, we have shown that both antioxidant
and sensitizer activated this pathway but differed in inducing conformational changes of Keap1.
SFN promoted the formation of intramolecular disulfide bonds whereas TNBS promoted the
formation of intramolecular disulfide bonds of Keap1. Another innovative finding of this study is
the identification of ARE4 to support Nrf2 repression, given the fact that Nrf2 is generally
considered to confer transactivation activity.

Interestingly, Nrf1, commonly referred as to

functionally related to Nrf2 [17], exhibited opposite activity toward the ARE4 reporter, pointing to
an important difference in their molecular recognition. Finally, we have shown that the S/ARE
element was activated the most among several well-established Nrf2 elements.
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MATERIALS AND METHODS
Hanks balanced salt solution, TNBS and William’s medium E (WME) were purchased from
Sigma (St. Louis, MO). SFN was purchased from Alexis (San Diego, CA). Dulbecco’s Modified
Eagles Medium (DMEM), high fidelity Platinum Taq DNA polymerase, insulin-transferrinselenium (ITS) G supplement were purchased from Invitrogen (Carlsbad, CA). Dual-Luciferase
Reporter Assay System was from Promega (Madison, WI). Fetal bovine serum (FBS) was from
HyClone laboratories (Logan, UT). The antibody against glyceradehyde-3-phosphate dehydrogenase (GAPDH) was from Abcam (Cambridge, UK), and the antibody against Nrf2 (C-20) was
from Santa Cruz Biotechnology (Santa Cruz, CA). The goat anti-rabbit IgG conjugated with
horseradish peroxidase was from Pierce (Rockford, IL). Plated human primary hepatocytes
were obtained from the Liver Tissues Procurement and Distribution System (University of
Minnesota) or CellzDirect (Pittsboro, NC).

Human dermal fibroblasts (cryopreserved) were

purchased from Cascade Biologics (Portland, OR).

Unless otherwise specified, all other

reagents were purchased from Fisher Scientific (Fair Lawn, NJ).

Reporter constructs and cotransfection assays
CES1A1 promoter reporters were prepared to contain various lengths of CES1A1 genomic
sequence. All promoter reporters were subcloned from the CES1A1-6560-Luc reporter. This
reporter was prepared by inserting the genomic fragment from -6560 to -21 (relatively to the
translation initiation codon) into the pGL3 basic vector through Mlu I and Xho I sites. All cloning
and subcloning were performed by PCR with high fidelity Platinum Taq DNA polymerase. To
prepare the CES1A1-3582m-Luc reporter, site-directed mutagenesis was performed as
described previously [35]. Complementary oligonucleotides (5’-CTCACCCATCACAATGTACTGAGGAATCATGAAGCAGAAA-3’) were synthesized to introduce substitutions (underlined).
The primers were annealed to the CES1A1-3582-Luc reporter and subjected to a thermocycler
for a total of 15 cycles. The resultant PCR-amplified constructs were then digested with Dpn I to
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remove the non-mutated parent construct. The mutated PCR-amplified constructs were used to
transform XL1-Blue bacteria. To prepare element reporters, oligonucleotides (Table I) were
synthesized, annealed and ligated into the pGL3 promoter vector through Nhe I and Xho I. All
reporter constructs were subjected to sequence analysis. To determine the reporter activities,
cotransfection in Huh7 cells was performed.

Transfection mixtures contained 100 ng of a

reporter plasmid and 0.2 ng of CMV-Renilla luciferase plasmid. In some cases, Nrf1 and Nrf2
constructs were included. Nrf1 construct was a gift of Dr. Jefferson Y. Chan of University of
California Irvine whereas Nrf2 construct was purchased from OriGene (Rockville, MD). The
corresponding vector was used to equalize the total amount of plasmid DNA. Typically, cells
were transfected for 12 h and the medium was replaced with fresh medium supplemented with
1% FBS.

The treatment lasted for 24 h and the cells were washed once with phosphate

buffered saline and collected by scraping. The reporter enzyme activities were assayed with a
Dual-Luciferase Reporter Assay System as described previously.

Electrophoretic mobility shift assay (EMSA)
The EMSA experiment was performed as described previously [36].

Nuclear extracts of Huh7

cells treated with SFN (10 M) for 24 h were prepared with the nuclear and cytoplasmic
extraction kit (Pierce, Rockford, IL). The sense and antisense oligonucleotides (Table I) were
annealed by heating at 94°C for 5 min followed by gradually cooling to room temperature. The
sense strand was synthesized as labeled or non-labeled form (for competition). Nuclear protein
(5 μg) was incubated with a double-stranded biotinylated probe (0.1 pmol) at room temperature
for 20 min. In competition assays, nuclear extracts were first incubated with an unlabeled probe
at a 25x or 100x excess for 5 min before addition of the labeled probe. For antibody-disruption
assay, the nuclear extracts were first incubated with an antibody against Nrf2 (C-20) on ice for
20 min and then with the labeled probe. The protein-DNA complexes were resolved by nondenaturing polyacrylamide gel electrophoresis (5%) and transferred onto a Biodyne® nylon
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membrane.

The biotinylated probe was detected with streptavidin-conjugated horseradish

peroxidase and chemiluminescent substrate (PIERCE, Rockford, IL). The chemiluminescent
signal was captured by KODAK Image Station 2000, and the relative intensities were quantified
by KODAK 1D Image Analysis Software (KODAK Molecular Imaging Software, Version 4.0,
Rochester, NY).

Chromatin immunoprecipitation (ChIP)
ChIP experiment was performed, essentially described previously [36, 37]. Huh7 Cells were
treated with SFN (10 µM) for 24 h, washed and underwent cross-linking for 15 min by 1.0%
formaldehyde at room temperature, and the cross-linking was terminated with glycine (final
concentration of 125 mM). The soluble chromatins were prepared as described previously [36].
For ChIP experiment, chromatins were pre-cleared for 2 h at 4°C with protein G beads pretreated with herring sperm DNA (0.2 mg/ml) and BSA (0.5 mg/ml). A fraction of the pre-cleared
chromatins was stored at -80°C for later use as an input. An antibody against Nrf2 was added
into the pre-cleared chromatins, and an overnight incubation at 4°C was performed.

As a

negative control, incubation was performed with pre-immune IgG. The antibody-bound
chromatins and DNA input were analyzed by PCR for the presence of the genomic fragments
containing the Nrf2-bound element with primers shown in Table I. The PCR was performed with
Platinum Taq DNA polymerase for a total of 32 cycles at 94C for 30 s, 58C for 30 s and 68C
for 60 s. A 3-min initial denaturation was performed.

Other analyses Protein concentrations were determined with BCA assay (Pierce) based on
albumin standard. Western analysis and the preparation of anti-CES1 antibody were described
elsewhere (37-39). RT-qPCR with Taqman probes was performed as described previously [40].
The Taqman probe identification numbers were: Hs00275607_m1 for CES1, Hs00168547_m1
for NAD(P)H:quinine oxidoreductase 1 (NQO1), 4352934E for GAPDH and Hs00172187_m1 for
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RNA polymerase II. Data are presented as mean  SD of at least three separate experiments,
except where results of blots are shown in which case a representative experiment is depicted
in the figures.

All data were analyzed for statistical significance with PASW Statistics 18.

Significant differences were made according to One-way ANOVA followed by a DUNCAN’s
multiple comparison test (p < 0.05).

Bars assigned different letters indicate statistical

significance among data-points.
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Table I Sequences of Oligonucleotides
Oligonucleotide
Native promoter reporters
CES1A1-6560-MluI
CES1A1-6448-MluI
CES1A1-5017-MluI
CES1A1-3582-MluI
CES1A1-3432-MluI
CES1A1-2293-MluI
CES1A1-1426-MluI
CES1A1-3552-MluI
CES1A1-3532-MluI
CES1A1-3512-MluI
CES1A1-3492-MluI
CES1A1-3482-MluI
CES1A1-10484XhoI

Sequence
5'-CTGCAACCTTCCCATCTCAGCTGTGACCCA-3’
5'-AGCTAATGAATAGGATCTGGGTTTATAATC-3’
5'-CAATACCCTAATTTCGATCTCTGAATGACC-3’
5'-TATTGCTTACAGCTGAAGTG-3’
5'-CAGGCAAAACCTAGGAGTGG-3’
5'-TGATTAGAATATCTTCCTGATGTATAAAAG-3’
5'-GATGTTTTCCAGCTTCATCCACGTTGTAGC-3’
5'-GTTATATGTATTAAGCAAAA-3’
5'-TTAGATCTATTGTAAGGCT-3’
5'-TGGTAGGCTCCAGCCTCACC-3’
5'-CATCACAATCTGCAGAGTCA-3’
5'-TGCAGAGTCATCATGAAGCA-3’
5’-ATACACTCGAGTCGGGGCCTGCGAGGTCTCTGTGCAGTTCA-3’

Element reporters
CES1A1-S/ARE
CES1A1-ARE4
CES1A2-S/ARE
AKR1C2-ARE
GCLM-ARE
GCLC-ARE
NQO1-ARE

5’-CACAATCTGCAGAGTCATCATGAAG-3’
5’-TTAAGATCGTGAGACAGCATTAATC-3’
5’-CACAATCTGCAGAATCATCATGAAC-3’
5’-TTGATGCAGTCAGGGTGACTCAGCAGCT-3
5’-GAAGACAATGACTAAGCAGAAATC-3’
5’-CCTCCCCGTGACTCAGCGCTTTGT-3'
5’-AGTCACAGTGACTCAGCAGAATCT-3’

EMSA
CES1A1-S/ARE
CES1A1-S/ARE(mutant)
CES1A1-ARE4

5’-CACAATCTGCAGAGTCATCATGAAG-3’
5’-CACAATGTACTGAGGAATCATGAAG-3’
5’-TTAAGATCGTGAGACAGCATTAATC-3’

ChIP
P1
P2
P3
P4

5’- TATTGCTAGCCTGAAGTGTTGCAGGGGAGTT-3’
5’- ACACCTCGAGCTGGCTCTTGGCCTATGAAGA-3’
5’- ATAAGCTAGCTGAGTTGAGCCTATGTATTAG-3’
5’- CATTCTCGAGTCCTGGCTGTAATCTTGTCAG-3’
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LEGENDS FOR FIGURES
Fig. 1. Induction of CES1 by SFN and TNBS in human dermal fibroblast, human primary
hepatocyte, and skin sarcoma line HT1080 and hepatoma line Huh7 Cells were cultured in
12-well plates and were treated with SFN (10 µM), TNBS (10 µg/ml) or DMSO for 24 h. Total
RNA was isolated and subjected to qRT-PCR analysis for the level of CES1 mRNA (A-D) by
Taqman probes as described in the section of Materials and Methods. The signals from each
target were normalized based on the signal from GAPDH and polymerase II and expressed as
mean  SD. Four individual donors were tested on human dermal fibroblasts, five on human
hepatocytes and three separate experiments were performed on cell lines. The asterisk signs
indicate statistical significance (P < 0.05) from DMSO-treated cells.

To determine the

corresponding induction at the protein level, lysates (20 µg) from control and treated Huh7 cells
were subjected to SDS-PAGE and transferred electrophoretically to Trans-Blot nitrocellulose
membranes. The immunoblots were blocked in 5% non-fat dry milk, incubated with the antibody
against CES1 or GAPDH. The blots were detected with chemiluminescent substrate (E).

Fig. 2. Identification of sensitizing/antioxidant response element (A) Activation of CES1A1
reporters by SFN, TNBS or Nrf2 Huh7 cells in 48 well-plates were transiently transfected by
GenJet version II.

For the SFN and TNBS treatment experiment, the transfection mixture

contained 50 ng of a reporter and 0.2 ng of the CMV-Renilla luciferase plasmid.

After

incubation at 37C for 12 h, the transfected cells were treated with SFN (10 µM), TNBS (10
µg/ml) or the same volume of DMSO for 24 h. Luciferase activities were determined with a
Dual-Luciferase Reporter Assay System and the reporter activity was expressed as fold of
activation. For the Nrf2 experiment, the transfection mixture contained 50 ng of a reporter and
0.2 ng of the CMV-Renilla luciferase plasmid, along with 10 ng Nrf2 expression construct or the
corresponding vector. (B) Identification of CES1A1 Nrf2 response element To further narrow
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down the sequence that supports the responsiveness to Nrf2, the CES1A1-3582-Luc was
further shortened from the 5’ end by 20 or 10 bases, and cotransfection was then performed as
described above. Data were collected from three independent experiments.

Fig. 3. Analyses of the S/ARE element by EMSA and ChIP (A) EMSA analysis Nuclear
extracts (5 μg) from Huh7 cells treated with SFN (10 µM) were incubated with a biotinylated
probe containing the S/ARE element (0.1 pmol) for 20 min. In the competition assay, nuclear
extracts were pre-incubated with the unlabeled S/ARE element, S/ARE mutant or ARE4 at 25x
or 100x excess for 5 min, and then incubated with the biotinylated probe. In disruption assay,
nuclear extracts were incubated first with an antibody against Nrf2 on ice for 20 min and then
with the biotinylated probe. The protein-DNA complexes were electrophoretically resolved and
transferred to a Biodyne® nylon membrane.

The biotinylated probe was located with

streptavidin-conjugated horseradish peroxidase and chemiluminescent substrate.

(B) ChIP

analysis Huh7 Cells were treated with SFN (10 µM) for 24 h, washed and underwent crosslinking for 15 min by 1% formaldehyde, and the cross-linking was terminated with 125 mM
glycine.

The soluble chromatins were prepared, pre-cleared with protein G beads and

incubated with anti-Nrf2 antibody or pre-immune IgG. The antibody-bound chromatins and DNA
input (1/20 of the antibody-bound chromatins) were analyzed by PCR for the presence of the
genomic fragments containing the Nrf2-bound element with the primers indicated in the diagram.
The primer sequences are shown in Table I.

Fig. 4. Functional characterization of the S/ARE element (A) Activation of S/ARE containing
or disrupting reporter by SFN Huh7 cells were transiently transfected by a reporter (50 ng) of the
S/ARE-Luc, CEA1A1-3582-Luc or its mutant CES1A1-3582m-Luc along with 0.2 ng of the
CMV-Renilla luciferase plasmid. After incubation at 37C for 12 h, the transfected cells were
treated with SFN (0-10 µM) or the same volume of DMSO for 24 h. Luciferase activities were
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determined and the reporter activity was expressed as fold of activation.

(B) Activation of

S/ARE containing or disrupting reporter by TNBS Huh7 cells were transiently transfected as
described above but treated with TNBS (0-10 µg/ml). Likewise, the reporter activities were
determined. (B) Activation of S/ARE containing or disrupting reporter by Nrf2 Huh7 cells were
transiently transfected with 50 ng reporter and 0.2 ng of the CMV-Renilla luciferase plasmid
along with 0-20 ng Nrf2 expression construct. The corresponding vector was used to equalize
the amount of total plasmid. The luciferase activities were determined 24 after the transfection.
*Statistically significant from the controls.

Fig. 5. Differential activation of various ARE reporters by Nrf1 and Nrf2 Huh7 cells were
transiently transfected by a reporter (50 ng) and the CMV-Renilla luciferase plasmid (0.2 ng)
along with 10 ng Nrf1, Nrf2 or the vector. The luciferase activities were determined 24 h after
the transfection. The core-Nrf2 sequence from known Nrf2 target genes is shown in H.

Fig. 6. Diagrammatical presentation of regulated transcription of the CES1A1 through the
S/ARE and ARE4 elements The relative width of the arrows between Nrf2 to small Maf and
Nrf2 to YY1 suggests the dominance of the formation of Nrf2-Maf dimmers over that of Nrf2YY1 dimers.

The double ended arrow between the Nrf2-YY1 dimers and the YY1-Nrf2

composite element suggests weak interaction.
interactions.
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